Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for MK-3475

6 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Treatment

    VICCMD16159

    11/07/2017

    A Phase 1/2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination with Pembrolizumab and Epacadostat in Subjects with Advanced Solid Tumors and Previously Treated Stage IIIB or Stage IV Non?Small Cell Lung Cancer and Stage IV Microsatellite-Stable Colorectal Cancer

    Treatment

    VICCMEL16138

    09/08/2017

    A Phase 1/2 Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination with Ipilimumab or Pembrolizumab in Patients with Metastatic Melanoma

    Treatment

    VICCMD1710

    08/03/2017

    A Phase 1/2, Open-Label, Dose-Escalation, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination with a PD-1 Inhibitor and Chemotherapy in Subjects with Advanced or Metastatic Solid Tumors (ECHO-207)

    Treatment

    ECOGBRES1418

    03/17/2017

    A Randomized, Phase III Trial to Evaluate The Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (yPN+) After Neoadjuvant Chemotherapy

    Treatment

    VICCMD1649

    12/14/2016

    A Phase 1b/2, Open-label, Dose Escalation Study of Entinostat in Combination with Pembrolizumab in Patients with Non-small Cell Lung Cancer, with Expansion Cohorts in Patients with Non-small Cell Lung Cancer, Melanoma, and Mismatch Repair-Proficient Colorectal Cancer

    Treatment

    VICCPED1620

    12/08/2016

    A Phase I/II Study of Pembrolizumab (MK-3475) in Children with Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma


    Print this page for your doctor